Certified AI for
Medical Use Cases
The core of our technology is our acoustic artificial intelligence "ResGuard Med". It is a CE-certified software as a medical device capable of detecting and analyzing respiratory symptoms such as cough.
​
ResGuard Med is available as a software development kit for smart devices, as an API for web browsers, and as a white-label smartphone app. We support different use cases and technological platforms ranging from smartphones to proprietary IoT devices.
Performance of ResGuard Med
A Proven Track Record Since 2016
9 years of medical research
Resmonics is a spin-off from ETH Zurich and the University of St. Gallen. The research behind ResGuard Med started in 2016 with the "Asthma Control Prediction" multicenter trial: Using only nocturnal cough, 75% of asthma attacks were predicted up to 4 days in advance. International replication studies are currently ongoing.
.jpeg)
Scientific focus and excellence
Resmonics and its partners have made scientific contributions ranging from infection wave prediction in hospitals and healthcare facilities to establishing cough frequency as a novel biomarker for pneumonia. Reach out to us if you are an academic institution interested in cutting-edge research in digital biomarkers and medical AIoT.
Strong and diverse partnerships
Resmonics is supported by a strong medical, commercial, and technological advisory board. Our international customer base consists of leading hospitals, pharmaceutical companies, MedTech companies, hospital suppliers, and health insurances. The company is supported by leading players in the Swiss healthtech ecosystem.